• 421 patients randomized at 38 European trial centers


• Top-line results expected in Q3, 2017

 

EPALINGES, Switzerland, February 8, 2017 – Anergis, a company developing proprietary ultra-fast allergy immunotherapy, announced today that it has completed patient recruitment in the ATIBAR trial, a Phase IIb field-based clinical trial with Anergis’ lead compound AllerT for patients with birch pollen allergy.

More information